Control subjects | Patients with RA | |||
---|---|---|---|---|
Percent efflux β coefficient (95% CI) | p Value | Percent efflux β coefficient (95% CI) | p Value | |
Age, years | −0.9 (−0.4 to 0.2) | 0.50 | −0.2 (−0.2 to 0.1) | 0.78 |
Male sex | −0.9 (−4.6 to 2.8) | 0.62 | −6.1 (−9.4 to 2.8) | 0.000 |
Body mass index | −0.2 (−0.6 to 0.1) | 0.20 | 0.2 (−0.1 to 0.5) | 0.21 |
Abdominal circumference | −0.1 (−0.2 to 0.0) | 0.058 | 0.0 (−0.1 to 0.2) | 0.42 |
Systolic blood pressure | −0.1 (−0.2 to 0.0) | 0.025 | 0.1 (−0.0 to 0.2) | 0.11 |
Diastolic blood pressure | −0.0 (-0.1 to 0.0) | 0.29 | 0.01 (−0.0 to 0.2) | 0.15 |
Cardiovascular comorbidities | ||||
Smoking | 1.8 (−2.4 to 6.0) | 0.40 | −0.3 (−4.5 to 3.9) | 0.89 |
Diabetes | 1.2 (−5.9 to 8.3) | 0.74 | 2.9 (−1.3 to 7.2) | 0.17 |
Hypertension | −2.4 (−6.0 to 1.1) | 0.17 | 0.1 (−3.0 to 3.2) | 0.95 |
Dyslipidemia | −1.1 (−5.2 to 3.1) | 0.61 | −0.3 (−3.4 to 2.8) | 0.85 |
Antihypertensive treatment | 0.7 (−3.6 to 5.0) | 0.75 | 0.4 (−2.7 to 3.5) | 0.80 |
Statins | −2.1 (−7.4 to 3.2) | 0.44 | 0.6 (−2.6 to 3.8) | 0.70 |
Laboratory examinations, including lipid profile | ||||
ESR | −0.2 (−0.1 to 0.1) | 0.23 | −0.1 (−0.1 to 0.0) | 0.12 |
CRP | −0.3 (−0.6 to 0.0) | 0.092 | −0.0 (−0.1 to 0.1) | 0.83 |
Cholesterol | 0.0 (−0.0 to 0.1) | 0.11 | 0.00 (−0.0 to 0.00) | 0.69 |
Triglycerides | −0.0 (−0.1 to 0.0) | 0.19 | 0.0 (−0.0 to 0.0) | 0.30 |
HDL cholesterol | 0.1 (−0.0 to 0.2) | 0.092 | 0.0 (−0.1 to 0.1) | 0.48 |
LDL cholesterol | 0.0 (−0.0 to 0.1) | 0.32 | −0.0 (−0.1 to 0.0) | 0.62 |
Lipoprotein A | 0.1 (−0.0 to 0.1) | 0.059 | −0.0 (−0.0 to 0.0) | 0.35 |
Apolipoprotein A | 0.0 (−0.0 to 0.1) | 0.089 | −0.0 (−0.1 to 0.0) | 0.84 |
Apolipoprotein B | 0.0 (−0.1 to 0.1) | 0.77 | 0.00 (−0.0 to 0.0) | 0.99 |
ApoB/ApoA ratio | −5.8 (−16.8 to 5.4) | 0.31 | 0.8 (−4.1 to 5.7) | 0.76 |
Atherogenic index | 0.7 (−2.4 to 1.0) | 0.41 | 0.0 (−1 to 1) | 0.99 |
Rheumatoid arthritis-related data | ||||
Disease duration | 0.1 (−0.0 to 0.3) | 0.12 | ||
DAS28 | −1.1 (−2.3 to 0.2) | 0.086 | ||
Remission | – | |||
Low disease activity | −5.2 (−10.0 to 0.3) | 0.039 | ||
Moderate disease activity | −4.6 (−8.5 to 0.7) | 0.020 | ||
High disease activity | −3.2 (−8.1 to 1.7) | 0.19 | ||
Moderate and high disease activity | −4.2 (−7.9 to 0.6) | 0.024 | ||
DAS28-CRP | −1.1 (−2.7 to 0.4) | 0.14 | ||
SDAI | −0.0 (−0.1 to 0.1) | 0.54 | ||
CDAI | −0.0 (−0.0 to 0.0) | 0.31 | ||
Rheumatoid factor | −0.4 (−3.8 to 2.9) | 0.81 | ||
ACPA | 0.4 (−2.7 to 3.6) | 0.78 | ||
Prednisone intake | −0.3 (−3.4 to 2.9) | 0.88 | ||
Prednisone dose | −0.3 (−3.4 to 2.9) | 0.88 | ||
NSAIDs | 4.6 (1.5 to 7.6) | 0.004 | ||
DMARDs | −0.2 (−4.6 to 4.2) | 0.93 | ||
Methotrexate | 0.5 (−2.9 to 4.0) | 0.77 | ||
Leflunomide | −1.3 (−5.9 to 3.3) | 0.58 | ||
Biologic therapy | 3.57 (−0.0 to 7.2) | 0.052 | ||
Anti-TNF-α therapy | 0.7 (−4.0 to 5.5) | 0.76 | ||
Tocilizumab | 8.0 (2.3 to 13.7) | 0.007 | ||
Rituximab | 1.3 (−9.1 to 11.7) | 0.81 | ||
Abatacept | −1.4 (−14.1 to 11.4) | 0.83 |